Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- adalimumab terapeutické užití MeSH
- antiflogistika terapeutické užití MeSH
- azathioprin terapeutické užití MeSH
- cékum chirurgie MeSH
- Crohnova nemoc diagnostické zobrazování farmakoterapie chirurgie MeSH
- dítě MeSH
- gastroskopie MeSH
- ileum chirurgie MeSH
- imunosupresiva terapeutické užití MeSH
- infliximab terapeutické užití MeSH
- kojenec MeSH
- kolonoskopie MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- následné studie MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- prospektivní studie MeSH
- recidiva MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- adalimumab MeSH
- antiflogistika MeSH
- azathioprin MeSH
- imunosupresiva MeSH
- infliximab MeSH
OBJECTIVES: Intestinal surgery is an important part of Crohn disease (CD) treatment in children. The aim of the present study was to compare the rate of endoscopic recurrence at the sixth month after ileocecal resection (ICR) in children with CD treated with azathioprine between patients who received prior antitumor necrosis factor alpha (anti-TNF-α) therapy and those who were not administered this therapy. Moreover, we tried to identify the potential risk factors for disease recurrence and describe the schedule of long-term follow-up after surgery. METHODS: We prospectively collected data from pediatric patients with CD, who underwent ICR between October 2011 and June 2015 at our hospital and were treated with azathioprine monotherapy after ICR. We evaluated the endoscopic recurrence (Rutgeerts score) at the sixth month after ICR in all included patients. RESULTS: Among 21 included patients, 13 achieved endoscopic remission (Rutgeerts score < i2) at the sixth month after ICR. No difference was found between patients who received prior anti-TNF-α therapy and those who did not. We did not find any clinically relevant factors associated with endoscopic recurrence rate at the sixth month. CONCLUSIONS: Prior anti-TNF-α therapy does not seem to be a strong risk factor for endoscopic recurrence within 6 months after ICR. Further studies on large sample of patients are needed to identify potential predictors of disease recurrence.
Citace poskytuje Crossref.org
Kono-S anastomosis in Crohn's disease: initial experience in pediatric patients